Clarivate PLC CLVT
We take great care to ensure that the data presented and summarized in this overview for CLARIVATE Plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CLVT
View all-
Leonard Green & Partners, L.P. Los Angeles, CA117MShares$477 Million14.1% of portfolio
-
Clarkston Capital Partners, LLC Bloomfield Hills, MI70.7MShares$289 Million6.92% of portfolio
-
Exor N.V. Amsterdam, P767.3MShares$275 Million100.0% of portfolio
-
Impactive Capital LP New York City, NY43MShares$176 Million9.4% of portfolio
-
Seth Klarman Baupost Group LLC | Boston, Ma36.3MShares$148 Million5.37% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD27.8MShares$114 Million0.02% of portfolio
-
Partners Group Holding Ag Baar Zug, V825.6MShares$105 Million10.15% of portfolio
-
Fil LTD Hamilton, D021.4MShares$87.5 Million0.11% of portfolio
-
Black Rock Inc. New York, NY20.4MShares$83.4 Million0.0% of portfolio
-
Glenview Capital Management, LLC New York, NY18.6MShares$75.9 Million2.39% of portfolio
Latest Institutional Activity in CLVT
Top Purchases
Top Sells
About CLVT
Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs. The company also provides Derwent products, which include Derwent Innovation, Techstreet, and IP Professional Services that enables its customers to evaluate the novelty of potential new products, confirm freedom to operate with respect to their product design, help them secure patent protection, assess the competitive technology landscape, and ensure that their products comply with required industry standards; CompuMark products, such as trademark screening, searching, and watching products and services for businesses and law firms; and MarkMonitor products, which helps enterprises to establish, manage, optimize, and protect their online presence. It serves government and academic institutions, life science companies, and research and development corporations in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc is headquartered in London, the United Kingdom.
Insider Transactions at CLVT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 15
2025
|
Henry Levy President, LS&H |
BUY
Grant, award, or other acquisition
|
Direct |
242,130
+23.45%
|
-
|
Mar 15
2025
|
Bar Veinstein President, A&G |
BUY
Grant, award, or other acquisition
|
Direct |
242,130
+17.28%
|
-
|
Mar 15
2025
|
James Gordon Samson President, IP |
BUY
Grant, award, or other acquisition
|
Direct |
242,130
+15.01%
|
-
|
Mar 15
2025
|
Tov Matitiahu S. Shem Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
726,392
+33.8%
|
-
|
Mar 15
2025
|
Michael M Easton Senior VP, Finance/CAO |
BUY
Grant, award, or other acquisition
|
Direct |
208,837
+27.71%
|
-
|
Mar 15
2025
|
William E. Graff EVP, Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
245,157
+27.74%
|
-
|
Mar 15
2025
|
Jonathan Mark Collins Executive Vice President/CFO |
BUY
Grant, award, or other acquisition
|
Direct |
302,663
+23.86%
|
-
|
Mar 14
2025
|
Andrew Miles Snyder Director |
BUY
Open market or private purchase
|
Indirect |
237,176
+23.15%
|
$948,704
$4.17 P/Share
|
Mar 12
2025
|
Jane L Okun Bomba Director |
BUY
Open market or private purchase
|
Indirect |
49,750
+50.0%
|
$199,000
$4.03 P/Share
|
Mar 11
2025
|
Jonathan Mark Collins Executive Vice President/CFO |
SELL
Other acquisition or disposition
|
Direct |
30,344
-4.37%
|
-
|
Mar 04
2025
|
Jonathan Mark Collins Executive Vice President/CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,321
-2.71%
|
$77,284
$4.15 P/Share
|
Mar 04
2025
|
Jonathan Mark Collins Executive Vice President/CFO |
BUY
Grant, award, or other acquisition
|
Direct |
44,311
+5.85%
|
-
|
Mar 04
2025
|
William E. Graff EVP, Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,525
-0.89%
|
$14,100
$4.15 P/Share
|
Mar 04
2025
|
William E. Graff EVP, Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,974
+1.97%
|
-
|
Mar 04
2025
|
Michael M Easton Senior VP, Finance/CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,062
-1.2%
|
$16,248
$4.15 P/Share
|
Mar 04
2025
|
Michael M Easton Senior VP, Finance/CAO |
BUY
Grant, award, or other acquisition
|
Direct |
9,282
+2.66%
|
-
|
Mar 04
2025
|
James Gordon Samson President, IP |
SELL
Payment of exercise price or tax liability
|
Direct |
4,965
-0.44%
|
$19,860
$4.15 P/Share
|
Mar 04
2025
|
James Gordon Samson President, IP |
BUY
Grant, award, or other acquisition
|
Direct |
35,448
+3.03%
|
-
|
Mar 03
2025
|
Saurabh Saha Director |
BUY
Open market or private purchase
|
Direct |
58,275
+41.54%
|
$233,100
$4.36 P/Share
|
Mar 03
2025
|
Wendell E. Pritchett Director |
BUY
Open market or private purchase
|
Direct |
22,857
+24.14%
|
$91,428
$4.38 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 4.09M shares |
---|---|
Open market or private purchase | 4.12M shares |
Bona fide gift | 239K shares |
Payment of exercise price or tax liability | 391K shares |
---|---|
Open market or private sale | 198K shares |
Other acquisition or disposition | 30.3K shares |